Innovation Pharma announced the next phase of Brilacidin Coronavirus testing begun
On May 5, 2020, Innovation Pharma reported it had executed a Material Transfer Agreement (MTA) with a leading…
Massachusetts Eye and Ear and Massachusetts General Hospital advancied gene-based COVID-19 vaccine
On May 5, 2020, Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham,…
SHERLOCK-based one-step test provided rapid and sensitive COVID-19 detection
On May 5, 2020, a team of researchers at the McGovern Institute for Brain Research at MIT, the…
LabCorp announced availability of COVID-19 antibody test
On May 5, 2020, LabCorp announced that its COVID-19 Immunoglobulin G (IgG) antibody test is now available for…
Pfizer and BioNTech dosed first participants in US as part of global COVID-19 mRNA vaccine development program
On May 5, 2020, Pfizer and BioNTech announced the first participants have been dosed in the U.S. in…
Athersys announced commencement of patient enrollment in MACOVIA Study, a pivotal phase 2/3 trial evaluating MultiStemﾮ cell therapy for COVID-19 induced ARDS
On May 5, 2020, Athersys announced the first patients have been enrolled in Athersysﾒ pivotal Phase 2/3 study…
Diffusion Pharma announced FDA Accelerated Review of TSC clinical development plan to treat COVID-19 patients with ARDS
On May 5, 2020, Diffusion Pharmaceuticals announced the FDA accelerated its review of the Companyﾒs clinical development plan…
ACON Laboratories announced international availability of SARS-CoV-2 rapid test
On May 5, 2020, ACON Laboratories announced the availability of its SARS-COV-2 IgG/IgM Rapid Test. ACONﾒs test is…
Biotechnology | COVID-19 | Diagnostics | Medical Device | Non-Profit Research | Pharmaceutical | Therapeutics
USPTO launched platform to facilitate connections between patent holders and potential licensees in key technologies
On May 4, 2020, the U.S. Patent and Trademark Office (USPTO) unveiled a new web-based intellectual property marketplace…
Biotechnology | COVID-19 | FDA
BIOFIRE respiratory panel 21 (RP21) with SARS-CoV-2 obtained FDA Emergency Use Authorization
On May 4, 2020, bioMerieux announced that BioFire Diagnostics, its subsidiary specialized in syndromic infectious disease testing, has…
Vir and Alnylam identified RNAi therapeutic development candidate, VIR-2703 (ALN-COV), targeting SARS-CoV-2 for treatment of COVID-19
On May 4, 2020, Vir Biotech and Alnylam Pharma announced the selection of a development candidate for VIR-2703,…
NanoViricides signed confidential disclosure agreement with international pharma company to explore collaboration on COVID-19 program
On May 4, 2020, NanoViricides announced that it has signed a Confidential Disclosure Agreement with a leading pharmaceutical…
Eli Lilly and Junshi Biosciences to co-develop antibody therapies for pevention and treatment of COVID-19
On May 4, 2020, Junshi Biosciences and Eli Lilly announced an agreement to co-develop therapeutic antibodies for the…
Mayo Clinic received $26 million from BARDA for COVID-19 convalescent plasma expanded access program
On May 4, 2020, Mayo Clinic was awarded a $26 million contract from the Biomedical Advanced Research and…
Arcturus Therapeutics and Catalent announced partnership to manufacture mRNA-Based COVID-19 vaccine
On May 4, 2020, Arcturus Therapeutics and Catalent announced a partnership to support the expected manufacture of Arcturusﾒ…
AbCellera identified antibodies for potential use in drugs to treat and prevent COVID-19
On May 3, 2020, AbCellera announced it had received a commitment of up to $175.6 million in support…
COVID-19 | FDA | Therapeutics
Gilead announced investigational antiviral remdesivir received FDA Emergency Use Authorization for treatment of COVID-19
On May 1, 2020, Gilead announced the FDA granted emergency use authorization (EUA) for the investigational antiviral remdesivir…
FDA issued Emergency Use Authorization for potential COVID-19 treatment
On May 1, 2020, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug remdesivir…
USC study showed Alzheimer’s gene triggers early breakdowns in the blood-brain barrier, predicting cognitive decline
On May 1, 2020, a University of Southern California (USC) study suggested that temporarily suppressing the body’s immune…
CDC launched the National Healthcare Safety Network COVID-19 Module Data Dashboard
On May 1, 2020, the CDC launched the National Healthcare Safety Network (NHSN) COVID-19 Module Data Dashboard showing…
US Dept of Veterans Affairs participated in drug, plasma trials in fight against COVID-19
On May 1, 2020, the U.S. Dept. of Veterans Affairs (VA) announced participation in a series of clinical…
CDC launched national viral genomics consortium to better map SARS-CoV-2 transmission
On May 1, 2020, the CDC launched the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance…
CHF Solutions shipped Aquadex product to COVID-19 specialty center in Minnesota
On May 1, 2020, CHF Solutions announced that it has shipped Aquadex product to a specialty care center…
Cancer patients face high mortality from COVID-19
On May 1, 2020, people with cancer who develop COVID-19 are much more likely to die from the…
Athersys and University Hospitals Cleveland Medical Center announce activation of first clinical site for MACOVIA study for COVID-19 Induced ARDS
On May 1, 2020, Athersys and University Hospitals Cleveland Medical Center (UH Cleveland) announced that UH Cleveland is…
XBiotech identified ‘super bloods’ for development of True Human COVID-19 therapy
On May 1, 2020, XBiotech announced that human immune donors had been identified that can support the Company’s…
FDA included ventilator developed by NASA in ventilator Emergency Use Authorization
On Apr. 30, 2020, the FDA included, under the ventilator emergency use authorization (EUA), a ventilator developed by…
Mesoblast began enrollment in phase 2/3 clinical trial of remestemcel-L in 300 patients with acute respiratory distress syndrome
On Apr. 30, 2020, Mesoblast announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic…
AstraZeneca and Oxford University announced landmark agreement for COVID-19 vaccine
On Apr. 30, 2020, AstraZeneca and the University of Oxford announced an agreement for the global development and…
Oxford University announced a landmark partnership for development of COVID-19 vaccine
On Apr. 30, 2020, University of Oxford announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for…